Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aravive (ARAV) stocks in Canada

Learn how to easily invest in Aravive stocks.

Aravive is a biotechnology business based in the US. Aravive stocks (ARAV.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.26 – a decrease of 11.64% over the previous week. Aravive employs 17 staff and has a trailing 12-month revenue of around $12.1 million.

How to buy shares in Aravive

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARAV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Aravive stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Aravive's stock price?

Since the stock market crash in March caused by coronavirus, Aravive's stock price has had significant negative movement.

Its last market close was $2.43, which is 72.82% down on its pre-crash value of $8.94 and 37.45% down on the lowest point reached during the March crash when the stocks fell as low as $3.34.

If you had bought $1,000 worth of Aravive stocks at the start of February 2020, those stocks would have been worth $418.92 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $252.60.

Aravive stock price (NASDAQ:ARAV)

Use our graph to track the performance of ARAV stocks over time.

Aravive shares at a glance

Information last updated 2022-01-10.
Latest market close$2.43
52-week range$2.16 - $9.95
50-day moving average $3.13
200-day moving average $4.29
Wall St. target price$22.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.60

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Aravive price performance over time

Historical closes compared with the close of $2.43 from 2022-01-14

1 week (2022-01-07) -11.64%
1 month (2021-12-16) -10.66%
3 months (2021-10-14) -36.55%
6 months (2021-07-16) -46.24%
1 year (2021-01-15) -58.53%
2 years (2020-01-16) -81.00%
3 years (2019-01-16) 3.9
5 years (2017-01-13) 15.8

Aravive financials

Revenue TTM $12.1 million
Gross profit TTM $-11,935,000
Return on assets TTM -28.11%
Return on equity TTM -58.32%
Profit margin -249.06%
Book value $2.60
Market capitalisation $57.9 million

TTM: trailing 12 months

Aravive share dividends

We're not expecting Aravive to pay a dividend over the next 12 months.

Have Aravive's shares ever split?

Aravive's shares were split on a 1:6 basis on 15 October 2018. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aravive shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Aravive shares which in turn could have impacted Aravive's share price.

Aravive share price volatility

Over the last 12 months, Aravive's shares have ranged in value from as little as $2.16 up to $9.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aravive's is 2.8373. This would suggest that Aravive's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aravive overview

Aravive, Inc. , a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc.

Stocks similar to Aravive

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site